Immuneering Corp (IMRX) Wheel Strategy

Running a IMRX wheel strategy lets you generate consistent premium income on Immuneering Corp while setting your own entry and exit prices on the underlying. Immuneering Corp's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own IMRX, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best IMRX wheel strategy setups in real time.

The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on IMRX, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable IMRX wheel from a losing one.

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the IMRX wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your IMRX wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.